Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria

  • Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile across the entire dose range tested
  • All doses provided clinically meaningful improvements with respect to the proportion of patients achieving UAS7=0 (complete absence of hives and itch) and UAS7≤6 (well-controlled disease activity) vs. placebo over the treatment period, starting as early as Week 1

…

/by

Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions

  • Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brands

  • Announced a planned 10-year commitment with historically black colleges and universities to address root causes of systemic disparities in health outcomes

  • Continued our global health leadership with positive phase 2b results for our next generation antimalarial therapy ganaplacide in combination with lumefantrine which support its continued development

  • Committed to achieving net zero …
/by